Navigation Links
URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
Date:1/8/2009

The University of Rochester Medical Center (URMC) has received a U.S. patent for a diagnostic technology that can rapidly and accurately screen for organisms such as bacteria and other infectious agents. Lighthouse Biosciences, LLC, a Rochester-based life sciences company, is the exclusive worldwide license holder of the technology.

The company's technology platform called NanoLantern is a novel method of identifying genetic sequences from biological samples, a process that can be used to detect any organism or genetic feature by identifying its unique DNA fingerprint. The NanoLantern consists of an array of DNA probes that can be programmed from a database of known genetic signatures to simultaneously screen for multiple individual targets using a single sample of blood, urine, cells, or other substance with organic content. The U.S. patent is being awarded for the process the technology uses to identify DNA sequences. The method, first developed by University of Rochester scientists in 2003, promises to be faster and more precise than other existing models.

"This patent represents an important milestone in developing the company's intellectual property portfolio," said Rand Henke, CEO of Lighthouse Biosciences. "It addresses a breakthrough method that will allow the company to design and make at a low cost a very wide range of probes for the detection of most pathogens."

The company is in the process of developing a prototype that consists of a series of disposable biosensor cartridges or labs on a chip that will be housed in a workstation that can be deployed in hospitals, doctor's offices, nursing homes, or any other health care setting.

While the technology has a wide array of potential applications in healthcare, agriculture, food safety, water quality, and national security, Lighthouse Biosciences is initially focused on the field of hospital-acquired infections (HAI). HAI are infections that patients receive during their care in a hospital or other health care facility such as a nursing home that are not related to any pre-existing medical condition. Despite extensive efforts in recent years to address the causes, HAI remain a massive burden on the U.S. health care system with more than 1 million annual cases and 90,000 associated deaths, all at a healthcare cost of $5.7 billon per year and at a cost to society of approximately $30 billion per year in the U.S.

One of the key challenges in combating HAI is the need to develop a system of surveillance that can identify these infections as early as possible. The current standard is to send potentially infectious samples out to a clinical laboratory for analysis and wait for the results. This process typically takes up to 2 to 3 days depending upon the proximity of the lab to the health care facility and the speed at which the lab can process the samples, a delay that can be an impediment to successful treatment. The NanoLantern technology has demonstrated the ability to provide results rapidly within 15 minutes and do so at the point of care.

The largest category of HAIs is urinary tract infections, which account for 40% of all infections. Lighthouse Biosciences, in cooperation with the URMC Departments of Urology and Microbiology and Immunology is currently conducting clinical studies to test the screening system at URMC's Strong Memorial Hospital.

The underlying technology for the company's NanoLantern platform was first developed by University of Rochester scientists Benjamin Miller, Ph.D., Todd Krauss, Ph.D. and Christopher Strohsahl, Ph.D. In addition to faculty appointments at the University, all three also hold corporate positions and/or equity positions in the company. Lighthouse Biosciences L.L.C., which was founded by the scientists in 2005, is based in the Lennox Tech Enterprise Center in Henrietta.


'/>"/>

Contact: Mark Michaud
mark_michaud@urmc.rochester.edu
585-273-4790
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. URMC, FDA to collaborate on national data repository for heart research
2. Position Statement Regarding Lt. Gov. Paterson from Tara A. Cortes, Ph.D, RN President and CEO of Lighthouse International
3. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
4. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
5. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
6. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
7. Cell Biosciences Introduces First Protein Analysis Kits
8. Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer
9. Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo
10. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
11. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 2016 , ... This week Omega Institute, a premier nonprofit educational retreat center ... October. Omega is offering a record 370 in-person workshops and new online learning ... widespread interest in or need for the knowledge and skills we’ve been cultivating for ...
(Date:5/2/2016)... ... 2016 , ... Dr. Rassouli, dentist in Orange County, CA comments ... research, which was published in the “Journal of the American Geriatrics Society,” more than ... Americans have Alzheimer’s disease. The study found that dental problems may increase the risk ...
(Date:5/2/2016)... , ... May 02, 2016 ... ... report that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants and ... these risks, Novus Medical Detox Center —a leading Florida-based drug treatment ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Sixth Annual Lifestyle Intervention ... Bellagio Hotel in Las Vegas, NV from October 17–19, 2016. The Nevada ... event. , This year’s conference will offer presentations featuring new treatment tracks, ...
(Date:5/2/2016)... ... May 02, 2016 , ... Consultative ... EVP and GM Jim Callandrillo and Duane Reed, VP of business development of ... Business Intelligence and Research Group (PBIRG) General Meeting from May 15-17 at ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Transparency Market Research has published ... Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... skincare devices market was valued at US$ 7,255.8 Mn ... CAGR of 10.1% from 2015 to 2023 to reach ... full Skincare Devices Market (Treatment Device - LED Therapy Devices, ...
(Date:4/27/2016)... , April 27, 2016 Tie-up ... initiative to save newborns   ... women & newborns in collaboration with Breast Milk Foundation (BMF), ... first Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This ... food source for infants and should be available to babies ...
(Date:4/27/2016)... -- Shire plc (LSE: SHP, NASDAQ: ... Officer, will present at the Deutsche Bank 41st Annual Health ... Wednesday, May 04, 2016, 10:00 am EDT (15:00 BST). ... Presentations and Webcasts section of Shire,s Investor website at ... available on this same website for approximately 90 days. ...
Breaking Medicine Technology: